10月8日，中国同全球疫苗免疫联盟签署协议，正式加入“新冠肺炎疫苗实施计划”。这是中国秉持人类卫生健康共同体理念、履行自身承诺推动疫苗成为全球公共产品的一个重要举措。

China signed an agreement with Gavi, the Vaccine Alliance, officially joining COVAX on Oct 8. This is an important step China has taken to uphold the concept of a shared community of health for all and to honor its commitment of turning COVID-19 vaccines into a global public good.

中国新冠疫苗研发完成并投入使用后，将作为全球公共产品，为实现疫苗在发展中国家的可及性和可担负性作出中国贡献。

COVID-19 vaccine development and deployment in China, when available, will be made a global public good. This will be China’s contribution to ensuring vaccine accessibility and affordability in developing countries.

——2020年5月18日，习近平在第73届世界卫生大会视频会议开幕式上的致辞

中方秉持人类命运共同体理念，愿同各国分享防控有益做法，开展药物和疫苗联合研发，并向出现疫情扩散的国家提供力所能及的援助。

Guided by the vision of building a community with a shared future for mankind, China will be more than ready to share our good practices, conduct joint research and development of drugs and vaccines, and provide assistance where we can to countries hit by the growing outbreak.

——2020年3月26日，习近平在二十国集团领导人特别峰会上的发言